Luis
Montuenga Badía
Catedrático de Universidad
Universitat de València
Valencia, EspañaPublicacions en col·laboració amb investigadors/es de Universitat de València (10)
2024
-
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Cell Death and Disease, Vol. 15, Núm. 11
2021
-
Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies
Cancers, Vol. 13, Núm. 12
2020
-
Comprehensive analysis of SWI/SNF inactivation in lung adenocarcinoma cell models
Cancers, Vol. 12, Núm. 12, pp. 1-14
-
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282
2019
-
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Scientific Reports, Vol. 9, Núm. 1
-
Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients
Journal of Clinical Medicine, Vol. 8, Núm. 12
2018
-
Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects
American Journal of Respiratory and Critical Care Medicine, Vol. 197, Núm. 9, pp. 1164-1176
2017
-
Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3203-3213
2015
-
Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma
Oral Diseases, Vol. 21, Núm. 7, pp. 899-904
2013
-
Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer
Journal of the National Cancer Institute, Vol. 105, Núm. 18, pp. 1385-1393